Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Provided By GlobeNewswire
Last update: Feb 6, 2025
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026
Read more at globenewswire.com2.6
+0.43 (+19.82%)
Find more stocks in the Stock Screener
SLRN Latest News and Analysis
2 days ago - ChartmillThese stocks are moving in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.
2 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.
